Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma
Dummer R, Sandhu S, Miller WH, Butler MO, Taylor MH, Heinzerling L, Blank CU, Couselo EM, Burris HA, Postow MA, Chmielowski B, Middleton MR, Berking C, Hassel JC, Gesierich AH, Mauch C, Kleha JF, Polli A, Harney AS, di Pietro A, Ascierto PA (2026)
Publication Type: Journal article
Publication year: 2026
Journal
Book Volume: 22
Pages Range: 995-1013
Journal Issue: 9
DOI: 10.1080/14796694.2026.2643481
Authors with CRIS profile
Involved external institutions
Universitätsspital Zürich (USZ)
Switzerland (CH)
The University of Melbourne
Australia (AU)
McGill University
Canada (CA)
University Health Network (UHN)
Canada (CA)
Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center
United States (USA) (US)
Klinikum der Universität München (LMU Klinikum)
Germany (DE)
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI / NKI-AVL)
Netherlands (NL)
Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron
Spain (ES)
Sarah Cannon Research Institute (SCRI)
United States (USA) (US)
Memorial Sloan Kettering Cancer Center
United States (USA) (US)
University of California Los Angeles (UCLA)
United States (USA) (US)
NIHR Oxford Biomedical Research Centre
United Kingdom (GB)
Universitätsklinikum Heidelberg
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Pfizer, Inc.
United States (USA) (US)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Italy (IT)
Switzerland (CH)
The University of Melbourne
Australia (AU)
McGill University
Canada (CA)
University Health Network (UHN)
Canada (CA)
Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center
United States (USA) (US)
Klinikum der Universität München (LMU Klinikum)
Germany (DE)
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI / NKI-AVL)
Netherlands (NL)
Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron
Spain (ES)
Sarah Cannon Research Institute (SCRI)
United States (USA) (US)
Memorial Sloan Kettering Cancer Center
United States (USA) (US)
University of California Los Angeles (UCLA)
United States (USA) (US)
NIHR Oxford Biomedical Research Centre
United Kingdom (GB)
Universitätsklinikum Heidelberg
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Pfizer, Inc.
United States (USA) (US)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Italy (IT)
How to cite
APA:
Dummer, R., Sandhu, S., Miller, W.H., Butler, M.O., Taylor, M.H., Heinzerling, L.,... Ascierto, P.A. (2026). Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma. Future Oncology, 22(9), 995-1013. https://doi.org/10.1080/14796694.2026.2643481
MLA:
Dummer, Reinhard, et al. "Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma." Future Oncology 22.9 (2026): 995-1013.
BibTeX: Download